- Home
- REVB vs CNSP Comparison
REVB vs CNSP Comparison
Compare REVB & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- CNSP
- Stock Information
- Founded
- REVB 2020
- CNSP 2017
- Country
- REVB United States
- CNSP United States
- Employees
- REVB N/A
- CNSP N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- CNSP Health Care
- Exchange
- REVB Nasdaq
- CNSP Nasdaq
- Market Cap
- REVB 3.8M
- CNSP 4.0M
- IPO Year
- REVB N/A
- CNSP 2019
- Fundamental
- Price
- REVB $2.58
- CNSP $5.09
- Analyst Decision
- REVB
- CNSP Hold
- Analyst Count
- REVB 0
- CNSP 1
- Target Price
- REVB N/A
- CNSP N/A
- AVG Volume (30 Days)
- REVB 164.5K
- CNSP 40.3K
- Earning Date
- REVB 08-08-2025
- CNSP 08-14-2025
- Dividend Yield
- REVB N/A
- CNSP N/A
- EPS Growth
- REVB N/A
- CNSP N/A
- EPS
- REVB N/A
- CNSP N/A
- Revenue
- REVB N/A
- CNSP N/A
- Revenue This Year
- REVB N/A
- CNSP N/A
- Revenue Next Year
- REVB N/A
- CNSP N/A
- P/E Ratio
- REVB N/A
- CNSP N/A
- Revenue Growth
- REVB N/A
- CNSP N/A
- 52 Week Low
- REVB $2.11
- CNSP $4.93
- 52 Week High
- REVB $168.00
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- REVB 45.75
- CNSP 21.28
- Support Level
- REVB $2.39
- CNSP $6.28
- Resistance Level
- REVB $2.70
- CNSP $7.75
- Average True Range (ATR)
- REVB 0.21
- CNSP 0.78
- MACD
- REVB 0.03
- CNSP -0.13
- Stochastic Oscillator
- REVB 51.61
- CNSP 3.96
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.